Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.58 |
| ▸ | CES1 | P23141 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL674157 | 0.84 | TSHR (0.50) | ALDH1A1ALOX15TDP1NPC1HPGD | |
| SCHEMBL38657491 | 0.84 | TSHR (0.50) | ALDH1A1ALOX15TDP1NPC1HPGD | |
| SCHEMBL8378855 | 0.82 | CES2 (0.62) | CES2CES1ALDH1A1ALOX15KMT2A | |
| SCHEMBL6062757 | 0.82 | CES2 (0.62) | CES2CES1ALDH1A1ALOX15KMT2A | |
| SCHEMBL3398637 | 0.82 | CES2 (0.62) | CES2CES1ALDH1A1ALOX15KMT2A | |
| SCHEMBL20599487 | 0.80 | CES2 (0.60) | CES2CES1ALDH1A1ALOX15KMT2A | |
| SCHEMBL28290973 | 0.79 | CES2 (0.65) | CES2CES1ALDH1A1ALOX15KMT2A | |
| SCHEMBL24288684 | 0.78 | CES2 (0.58) | CES2CES1ALDH1A1ALOX15KMT2A | |
| SCHEMBL513706 | 0.78 | CES2 (0.58) | CES2CES1ALDH1A1ALOX15KMT2A | |
| SCHEMBL21681966 | 0.78 | CES2 (0.58) | CES2CES1ALDH1A1ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238175-A1 | SOLID STATE FORMS OF VENETOCLAX AND PROCESSES FOR PREPARATION OF VENETOCLAX | ASSIA CHEM IND LTD (IL) | 2021-08-05 | — | — | US | disclosed |
| US-11001582-B2 | Solid state forms of Venetoclax and processes for preparation of Venetoclax | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2021-05-11 | — | — | US | disclosed |
| US-20190135806-A1 | SOLID STATE FORMS OF VENETOCLAX AND PROCESSES FOR PREPARATION OF VENETOCLAX | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2019-05-09 | — | — | US | disclosed |
| CN-106164076-B | Compound as ROS1 inhibitor | 詹森药业有限公司 | 2019-03-26 | — | — | CN | disclosed |
| EP-3426655-A1 | SOLID STATE FORMS OF VENETOCLAX AND PROCESSES FOR PREPARATION OF VENETOCLAX | Assia Chemical Industries Ltd. (IL) | 2019-01-16 | — | — | EP | disclosed |
| CN-105209448-B | Tricyclic compounds and uses thereof | 株式会社蒂奥姆生物 | 2018-09-14 | — | — | CN | disclosed |
| CN-108516974-A | Amide compounds for the treatment of HIV | 吉利德科学公司 | 2018-09-11 | — | — | CN | disclosed |
| CN-105705500-B | Amide compounds for the treatment of HIV | 吉利德科学公司 | 2018-05-29 | — | — | CN | disclosed |
| CN-108017603-A | Tricyclic compounds and uses thereof | 株式会社蒂奥姆生物 | 2018-05-11 | — | — | CN | disclosed |
| WO-2017156398-A1 | SOLID STATE FORMS OF VENETOCLAX AND PROCESSES FOR PREPARATION OF VENETOCLAX | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2017-09-14 | — | — | WO | disclosed |
| EP-3160967-A1 | IMIDAZO[1,2-A]PYRAZIN-1YL-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2017-05-03 | — | — | EP | disclosed |
| CN-105705500-A | Amide compounds for the treatment of HIV | 吉利德科学公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-105492008-A | Novel compounds and compositions for inhibition of fasn | FORMA THERAPEUTICS INC | 2016-04-13 | — | — | CN | disclosed |
| CN-105358151-A | Compounds for treating spinal muscular atrophy | HOFFMANN LA ROCHE | 2016-02-24 | — | — | CN | disclosed |
| WO-2015197503-A1 | IMIDAZO[1,2-A]PYRAZIN-1YL-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-30 | — | — | WO | disclosed |
| CN-105209448-A | Tricyclic compounds and uses thereof | SK CHEMICALS CO LTD | 2015-12-30 | — | — | CN | disclosed |
| EP-2044058-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007148070-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135806-A1 | SOLID STATE FORMS OF VENETOCLAX AND PROCESSES FOR PREPARATION OF VENETOCLAX | MCL1, PROC, PRKX | CES2 1532/4885CES1 1452/4885ALDH1A1 2583/4885 |
| US-11001582-B2 | Solid state forms of Venetoclax and processes for preparation of Venetoclax | MCL1, BCL9, U2AF1 | CES2 1500/4885CES1 1675/4885ALDH1A1 1722/4885 |
| US-20210238175-A1 | SOLID STATE FORMS OF VENETOCLAX AND PROCESSES FOR PREPARATION OF VENETOCLAX | MCL1, PROC, PRKX | CES2 1532/4885CES1 1452/4885ALDH1A1 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.